|
Middle Cerebral Artery Occlusion
|
0.090 |
Biomarker
|
disease |
BEFREE |
The number of Ki-67-, nestin-, or doublecortin-immunoreactive cells in bilateral subventricular zones was higher in EPO/EGFP/3T3-treated MCAO rats than it was in untreated MCAO control animals, indicating the enhancement of neurogenesis after EPO/EGFP/3T3 treatment.
|
30920178 |
2019 |
|
Middle Cerebral Artery Occlusion
|
0.090 |
Biomarker
|
disease |
BEFREE |
The ultrasound-mediated KLM and kallidinogenase treatments significantly increased the numbers of doublecortin-immunoreactive cells in the subventricular zone (SVZ) and laminin<sup>+</sup> cells in the peri-infarction region on day 7 after MCAO, compared with the other 3 groups (all P <.05).
|
29153395 |
2018 |
|
Middle Cerebral Artery Occlusion
|
0.090 |
Biomarker
|
disease |
BEFREE |
Furthermore, immunostaining assays indicated that BrdU/nestin- and BrdU/DCX-positive cells in EA-treated rats were significantly increased (P<0.05) when compared with the rats in the MCAO group, indicating EA may induce the proliferation and differentiation of endogenous neural stem cells (eNSCs) during cerebral ischemia-reperfusion.
|
30542450 |
2018 |
|
Middle Cerebral Artery Occlusion
|
0.090 |
Biomarker
|
disease |
BEFREE |
In an innovative approach, we used the DCX-Luc mouse, a transgenic model expressing luciferase in doublecortin-positive neuroblasts, to monitor the neurogenic response following middle cerebral artery occlusion over three weeks in three age groups (2, 6, 12months) by optical imaging while the stroke lesion was monitored by quantitative MRI.
|
28007584 |
2017 |
|
Middle Cerebral Artery Occlusion
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
HBO-PC increased pNF-H and DCX expression and mitigated cognitive deficits in MCAO rats.
|
28937253 |
2017 |
|
Middle Cerebral Artery Occlusion
|
0.090 |
Biomarker
|
disease |
BEFREE |
In addition, MCAO decreased the number of migrating neuroblasts (or DCX- and 5-ethynyl-2'-deoxyuridine-positive cells) in the cortex, subventricular zone, and hippocampus of the ischemic brain, followed by neurological injury (including brain infarct and neurological deficits).
|
29338384 |
2017 |
|
Middle Cerebral Artery Occlusion
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
Methyllycaconitine treatment increased cytomembrane FGFR1 expression and GFAP/BrdU-positive cells, upregulated the levels of phosphoinositide 3-kinase (PI3K) and phospho-Akt (pAkt), decreased nuclear FGFR1 expression, decreased the number of DCX-positive cells, and reduced the levels of DCX, PSA-NCAM, and Mash1 in the SVZ of MCAO mice compared with levels in vehicle-treated MCAO mice.
|
28551702 |
2017 |
|
Middle Cerebral Artery Occlusion
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
DCX expression is increased in subventricular zone (SVZ) cells migrating to the boundary of an ischemic lesion after induction of middle cerebral artery occlusion (MCAO) in adult rats and mice.
|
16962712 |
2006 |
|
Middle Cerebral Artery Occlusion
|
0.090 |
Biomarker
|
disease |
BEFREE |
Immunohistochemistry was performed to measure the expression of bromodeoxyuridine (BrdU), doublecortin (DCX), IGF-1 and IGF-1R at 7, 14 and 30 days after MCAo.
|
15567334 |
2004 |